The use of FAK inhibitors or AKT inhibitors can reduce the expression of CSC biomarkers, including CD133, CD44, NANOG, OCT4, c‐Myc and so forth, and limit CSC‐like features and colorectal cancer metastasis.217. The gene discussed is PROM1; the disease is colorectal cancer.